Three Or More Ring Hetero Atoms In The Tricyclo Ring System Patents (Class 544/250)
-
Publication number: 20090192178Abstract: In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J4, X, and R1-R5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.Type: ApplicationFiled: January 21, 2009Publication date: July 30, 2009Inventors: Julius J. Matasi, Deen Tulshian, Duane A. Burnett, Wen-Lian Wu, Peter Korakas, Lisa S. Silverman, Thavalakulamgara K. Sasikumar, Li Qiang, Martin S. Domalski
-
Publication number: 20090186879Abstract: There is provided a compound of the formula (I?): wherein x is a nitrogen or CRx, Rx is a hydrogen, etc., R1 is an optionally substituted hydrocarbon group, etc., R2 is an optionally substituted hydrocarbon group, etc., ring A is 5- to 8-membered heterocyclic ring, etc., and each of Y1, Y2 and Y3 is an optionally substituted carbon or a nitrogen, etc.; or a salt thereof or a prodrug thereof, which have CRF receptor antagonistic activity and use thereof.Type: ApplicationFiled: January 21, 2009Publication date: July 23, 2009Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Kazuyoshi Aso, Katsumi Kobayashi, Takafumi Takai, Takuto Kojima, Kazuyuki Tokumaru, Michiyo Mochizuki, Yasutaka Hoashi
-
Publication number: 20090185975Abstract: The invention provides a probe compound useful for early diagnosis of conformation disease, a composition and a kit comprising it for diagnosis for conformation disease, and a medical composition for treatment and/or prevention of conformation disease.Type: ApplicationFiled: December 25, 2006Publication date: July 23, 2009Applicant: TOHOKU UNIVERSITYInventors: Yukitsuka Kudo, Hiroyuki Arai, Nobuyuki Okamura, Masahiro Maruyama, Syozo Furumoto, Katsumi Doh-Ura
-
Publication number: 20090170882Abstract: Compounds, compositions and methods relating to kinesin inhibition are described herein.Type: ApplicationFiled: June 30, 2005Publication date: July 2, 2009Inventors: Dashyant Dhanak, Steven David Knight, Michael Lee Moore, Kenneth Alan Newlander
-
Publication number: 20090156554Abstract: New compounds of formula 1 are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory diseases of the gastro-intestinal tract and motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic conditions involving autoimmune reactions or inflammations of the kidney.Type: ApplicationFiled: February 5, 2009Publication date: June 18, 2009Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Steffen BREITFELDER, Udo MAIER, Trixi BRANDL, Christoph HOENKE, Matthias GRAUERT, Alexander PAUTSCH, Matthias HOFFMANN, Frank KALKBRENNER, Anne T. JOERGENSEN, Gerhard SCHAENZLE, Stefan PETERS, Frank BUETTNER, Eckhart BAUER
-
Patent number: 7547706Abstract: The invention concerns compounds of general formula (I): Wherein n, X, Y, R1 and R2 are as defined herein. The invention also concerns a method for preparing the compounds and their therapeutic use.Type: GrantFiled: October 17, 2007Date of Patent: June 16, 2009Assignee: Sanofi-AventisInventors: Jacques Froissant, Frank Marguet, Anne Olivier-Bandini, Frederic Puech
-
Publication number: 20090143399Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.Type: ApplicationFiled: August 20, 2007Publication date: June 4, 2009Applicants: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, SUPERGEN, INC.Inventors: Laurence H. Hurley, Daruka Mahadevan, Haiyong Han, David J. Bearss, Hariprasad Vankayalapati, Sridevi Bashyam, Ruben M. Munoz, Steven L. Warner, Kimiko Della Croce, Daniel D. Von Hoff, Cory L. Grand, James Welsh
-
Publication number: 20090137575Abstract: In its many embodiments, the present invention provides tetracyclic compounds of formula I or formula II (wherein the various moieties are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.Type: ApplicationFiled: December 17, 2008Publication date: May 28, 2009Inventors: Duane A. Burnett, Wen-Lian Wu
-
Publication number: 20090137604Abstract: Tri-heterocyclic compound of formula (I) wherein each of W, X and Y is carbon or nitrogen; each of U and Z is CR2, NR13, nitrogen, oxygen, sulfur etc.; A ring is carbocyclic ring, heterocyclic ring; R1 is alkyl, alkenyl, alkynyl, NR4R5, OR6 etc.; R3 is carbocyclic ring, heterocyclic ring; and a pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical comprising them as an active ingredient. A compound of formula (I) is useful, in order to possess corticotropin releasing factor receptor antagonistic activity, for the prevention and/or treatment of depression, anxiety, eating disorder, posttraumatic stress disorder, peptic ulcer, irritable bowl syndrome, Alzheimer's disease, drug addiction or alcohol dependence syndrome etc.Type: ApplicationFiled: September 2, 2008Publication date: May 28, 2009Applicant: ONO PHARMACEUTICAL CO., LTD.Inventors: Hisao NAKAI, Yoshifumi KAGAMIISHI
-
Publication number: 20090137583Abstract: The present invention provides 2-aminoquinazoline derivatives represented by formula (I): wherein R1 and R2 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, and the like; X represents a bond or CR7aR7b wherein R7a and R7b may be the same or different and each represents a hydrogen atom, and the like; when X is a bond, R3 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; when X is CR7aR7b wherein R7a and R7b have the same meanings as defined above, respectively, R3 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted aryl, and the like; R4 represents a hydrogen atom, hydroxy, substituted or unsubstituted lower alkoxy, and the like; and R5 represents a hydrogen atom, substituted or unsubstituted aryl, and the like, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 28, 2006Publication date: May 28, 2009Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Kuniyuki Kishikawa, Hidetomo Imase, Hajime Kashima, Kiyotoshi Mori, Toshihide Ikemura, Yoshisuke Nakasato, Misato Tomuro
-
Publication number: 20090131424Abstract: Disclosed are compounds of general formula (I), wherein the groups A, R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof as pharmaceutical compositions.Type: ApplicationFiled: January 9, 2009Publication date: May 21, 2009Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Trixi BRANDL, Udo MAIER, Christoph HOENKE, Anne T. JOERGENSEN, Alexander PAUTSCH, Steffen BREITFELDER, Matthias GRAUERT, Matthias HOFFMANN, Stefan SCHEUERER, Klaus ERB, Michael PIEPER, Ingo PRAGST
-
Patent number: 7524853Abstract: Thiophenepyrimidinone compounds and their use in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring inhibition of 17?-hydroxysteroid dehydrogenase enzymes.Type: GrantFiled: December 15, 2004Date of Patent: April 28, 2009Assignees: Solvay Pharmaceuticals B.V., Solvay Pharmaceuticals GmbHInventors: Leena Hirvelae, Nina Johansson, Pasi Koskimies, Olli Taneli Pentikaeinen, Tommi Nyroenen, Tiina Annamaria Salminen, Mark Stuart Johnson, Pekka Lehtovuori, Pauli Saarenketo, Bartholomeus Johannes Van Steen, Heinrich-Hubert Thole, Mikko Unkila, Josef Messinger, Johanna Kiviniemi, Lila Pirkkala, Bettina Husen
-
Publication number: 20090099168Abstract: Pyridopyrazine- and pyrimidopyrazine-dione compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the dihydroxypyridine carboxamides are of Formula I: wherein G, Q, bond a, R5, R6 and R7 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: December 9, 2008Publication date: April 16, 2009Inventors: Monica Donghi, Cristina Gardelli
-
Publication number: 20090099165Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.Type: ApplicationFiled: April 13, 2007Publication date: April 16, 2009Applicants: Arizona Board of Regents on Behalf of The University of Arizona, Montigen Pharmaceuticals, Inc.Inventors: Laurence H. Hurley, Daruka Mahadevan, Haiyong Han, David J. Bearss, Hariprasad Vankayalapati, Sridevi Bashyam, Ruben M. Munoz, Steven L. Warner, Kimiko Della Croce, Daniel D. Von Hoff, Cory L. Grand, James Welsh
-
Publication number: 20090093465Abstract: The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, and modulating protein kinase activity. Molecules of the invention can modulate casein kinase (CK) activity. The invention also relates in part to methods for using such molecules.Type: ApplicationFiled: August 29, 2008Publication date: April 9, 2009Applicant: Cylene Pharmaceuticals, Inc.Inventors: Fabrice PIERRE, Mustapha HADDACH
-
Patent number: 7511041Abstract: The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (PI3K) inhibition, especially for PI3K-? inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K-? activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoixnmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis.Type: GrantFiled: September 18, 2003Date of Patent: March 31, 2009Assignee: Bayer Pharmaceuticals CorporationInventors: Mitsuyuki Shimada, Toshiki Murata, Kinji Fuchikami, Hideki Tsujishita, Naoki Omori, Issei Kato, Mami Miura, Klaus Urbahns, Florian Gantner, Kevin Bacon
-
Publication number: 20090082336Abstract: In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J4, X, and R1-R5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.Type: ApplicationFiled: November 4, 2008Publication date: March 26, 2009Inventors: Julius J. Matasi, Deen Tulshian, Duane A. Burnett, Wen-Lian Wu, Peter Korakas, Lisa S. Silverman, Thavalakulamgara K. Sasikumar, Li Qiang, Martin S. Donalski
-
Publication number: 20090082374Abstract: The present invention provides tricyclic compounds, pharmaceutically acceptable salts, prodrugs, solvates, or hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting mitosis of cancerous cells.Type: ApplicationFiled: July 10, 2008Publication date: March 26, 2009Inventor: Aleem Gangjee
-
Publication number: 20090075970Abstract: Thieno- and furo-pyrimidine compounds are described, which are useful as H4 receptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the modulation of histamine H4 receptor activity and for the treatment of disease states, disorders, and conditions mediated by H4 receptor activity, such as inflammation.Type: ApplicationFiled: September 12, 2008Publication date: March 19, 2009Inventors: James P. Edwards, Danielle K. Neff, Deborah M. Smith, Jennifer D. Venable
-
Publication number: 20090076268Abstract: This invention concerns the synthesis of polycyclic structural components of pharmacological compounds, including the synthesis of fused benzofuro-heterocycles, through selective palladium-catalyzed cross-coupling and intramolecular cyclization.Type: ApplicationFiled: September 12, 2008Publication date: March 19, 2009Inventors: Anne E. Fitzgerald, Jing Liu, Neelakandha S. Mani
-
Patent number: 7501418Abstract: The invention concerns fused heterocyclic isoxazoline derivatives of Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof, more in particular, tetrahydropyranoisoxazole, hexahydroisoxazolopyridine, tetrahydrothiopyrano isoxazole and hexahydrobenzoisoxazole derivatives fused to a heterocyclic ring system via the 6-membered ring of the bicyclic moiety as well as processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine, in particular for treating depression, anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders including anorexia nervosa and bulimia, wherein the variables are defined as in Claim 1.Type: GrantFiled: August 13, 2003Date of Patent: March 10, 2009Assignee: Janssen Pharmaceutica, N.V.Inventors: José Ignacio Andrés-Gil, Manuel Jesús Alcázar-Vaca, José Manuel Bartolomé -Nebreda, Francisco Javier Fernández-Gadea, Margaretha Henrica Maria Bakker, Antonius Adrianus Hendrikus Megens
-
Publication number: 20090062318Abstract: The present invention provides tricyclic compounds having cytostatic and cytotoxic activity in a single molecule having receptor tyrosine kinase(s), dihydrofolate reductase, thymidylate synthase and/or dihydroorotate dehydrogenase inhibitory activity, which are useful as anti-angiogenic and anti-tumor agents. Also provided are methods of utilizing these inhibitors to treat tumor cells and other proliferative diseases and disorders.Type: ApplicationFiled: August 27, 2007Publication date: March 5, 2009Inventor: Aleem Gangjee
-
Patent number: 7498336Abstract: The present invention features 5-deazaflavin compounds, pharmaceutical compositions of 5-deazaflavin compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more 5-deazaflavin compounds of the invention.Type: GrantFiled: February 12, 2004Date of Patent: March 3, 2009Assignees: The United States of America as represented by the Secretary, Department of Health and Human Services, BioVeris CorporationInventors: Allan M. Weissman, Karen H. Vousden, Jane P. Jensen, Yili Yang, Shengyun Fang, Douglas Woods, John H. Kenten, Ilia Davydov, Yassamin J. Safiran, Pankaj Oberoi
-
Patent number: 7495096Abstract: Processes for the production of a compound of the following formula (I) by converting a compound of formula (II) with 2-pyrrolidone used in excess relative to compound (II) and processes for the production of a compound of formula (III). The latter process includes preparing compound (I); a reduction reaction which yields compound (III) in salt form; and liberating compound (III) from the salt.Type: GrantFiled: January 22, 2004Date of Patent: February 24, 2009Assignee: HF Arzneimittelforschung GmbHInventors: Joachim Moormann, Hans-Rainer Hoffmann, Rudolf Matusch
-
Patent number: 7491821Abstract: Compounds of formula 1 are modulators of P2X3 useful for the treatment of pain and genitourinary, gastrointestinal, and respiratory disorders: wherein R1 is —C(?S)CH3, pyridyl, pyrimidinyl, pyrazinyl, thiazolyl, furyl, furylcarbonyl, acetyl, or carbamoyl; R2a and R2b are independently H, methyl, or ethyl; R3 is H or methyl; Y is a bond, —(CR4R5)n— or —CR4?CR5—; wherein R4 and R5 are each independently H or methyl and n is 1 or 2; X is N or CH; A is phenyl, 5-membered heterocyclyl, or 6-membered heterocyclyl; R6, R7 and R8 are each independently H, halo, lower alkyl, cycloalkyl, alkylthio, alkylthio-lower alkyl, alkylsulfonyl-lower alkyl, di(lower alkyl)amino-lower alkyl, morpholinyl-lower alkyl, 4-methyl-piperazinyl-methyl, trifluoromethyl, pyridyl, tetrazolyl, thiophenyl, phenyl, biphenyl, or benzyl (where thiophenyl, phenyl and benzyl are substituted with 0-3 lower alkyl, halo, sulfonamido, trifluoromethyl, lower alkoxy or lower alkylthio) or R6 and R7 together form a 5-membered or 6-membered carbocyclType: GrantFiled: August 11, 2006Date of Patent: February 17, 2009Assignee: Roche Palo Alto LLCInventors: Christine E. Brotherton-Pleiss, Michael Patrick Dillon, Shelley K. Gleason, Clara Jeou Jen Lin, Ryan Craig Schoenfeld, Marzia Villa, Yansheng Zhai
-
Patent number: 7491729Abstract: 3-Substituted 3,4-dihydrothieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof. The invention relates to 3,4-dihydrothieno[2,3-d]pyrimidin-4-one derivatives which are substituted in position 3 by 5-membered heteroaryl which may be fused to an aryl or heteroaryl radical, where the heteroaryl and, if appropriate, the fused aryl or heteroaryl radical may have 1, 2 or 3 substituents selected independently of one another from C1-5-alkyl, C1-5-alkoxy, C1-5-alkylthio, halogen, CN, halo-C1-5-alkyl, halo-C1-5-alkoxy, hydroxy, —NH2, —N(R6)2, —NH(R6), aryl, aryloxy, aralkyl, aralkyloxy and heteroaryl, where the substituents aryl, aryloxy, aralkyl, aralkyloxy and heteroaryl may have 1, 2 or 3 substituents selected independently of one another from C1-5-alkyl, C1-5-alkoxy, C1-5-alkylthio, halogen, CN, halo-C1-5-alkyl, halo-C1-5-alkoxy, hydroxy, —NH2, —N(R6)2 and —NH(R6). The preparation and use of these derivatives, especially for therapeutic purposes, e.g.Type: GrantFiled: December 17, 2003Date of Patent: February 17, 2009Assignee: Abbott GmbH & Co. KGInventors: Margaretha Bakker, Wilfried Hornberger, Andreas Kling, Udo Lange, Helmut Mack, Achim Moeller, Reinhold Mueller, Kurt Schellhaas, Martin Schmidt, Gerd Steiner, Karsten Wicke
-
Publication number: 20090042912Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment, prevention or amelioration of a disease or disorder characterized by elevated ?-amyloid deposits or ?-amyloid levels in a patient.Type: ApplicationFiled: October 7, 2008Publication date: February 12, 2009Applicant: WyethInventors: Michael S. Malamas, James J. Erdei, Iwan S. Gunawan, Keith Douglas Barnes, Matthew Robert Johnson, Yu Hui
-
Publication number: 20090042873Abstract: The invention concerns tricyclic N-heteroarylcarboxamide derivatives containing a benzimidazole unit of general formula (I): Wherein A, P, Y, R1, R2 and R3 are as defined herein. The invention also concerns a method of preparing the compounds and their therapeutic use.Type: ApplicationFiled: August 1, 2008Publication date: February 12, 2009Applicant: SANOFI-AVENTISInventors: Laurent DUBOIS, Yannick EVANNO, Luc EVEN, Catherine GILLE, Andre MALANDA, David MACHNIK, Nathalie RAKOTOARISOA
-
Publication number: 20090029982Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the structure (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Z, L2 and w are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.Type: ApplicationFiled: April 28, 2006Publication date: January 29, 2009Applicant: SUPERGEN, INC.Inventors: David J. Bearss, Hariprasad Vankayalapati, Cory L. Grand
-
Publication number: 20090030196Abstract: Inhibitors of Pim kinases, ways to make them and methods of treating patients using them are disclosed.Type: ApplicationFiled: June 5, 2008Publication date: January 29, 2009Applicant: Abbott LaboratoriesInventors: Le Wang, Lisa A. Hasvold, Zhi-Fu Tao, Laura Hexamer, Thomas D. Penning
-
Publication number: 20090018149Abstract: Described are 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and pharmaceutically acceptable salts thereof, the use of these derivatives for the prophylaxis and/or treatment of mycobacteria-induced infections and opportunistic infections, as well as compositions containing at least one 4,5,6,7-tetrahydrobenzo[b]thiophene derivative and/or pharmaceutically acceptable salts thereof. Furthermore, the present application refers to the use of mycobacterial protein serine/threonine kinases for developing methods for detection and determination of these kinases for recognising and monitoring diseases and for controlling therapy of diseases.Type: ApplicationFiled: April 9, 2003Publication date: January 15, 2009Inventors: Andrea Missio, Gerald Bacher, Anil Koul, Axel Choidas, Peter Banhegyi, Zoltan Greff, Gyorgy Keri, Peter Marko, Laszlo Orfi, Janos Pato, Frigyes Waczek
-
Publication number: 20080318940Abstract: The invention relates to quinazolinone compounds of the formula wherein the R groups are defined in the specification, processes for their preparation and their use as pharmaceuticals, particularly in the treatment of disorders ameliorated by administration of TRPV1 antagonists.Type: ApplicationFiled: December 6, 2006Publication date: December 25, 2008Inventors: Edward Karol Dziadulewicz, Christopher Thomas Brain, Timothy John Ritchie, Andrew James Culshaw
-
Patent number: 7465739Abstract: Thiophenepyrimidinone compounds and their use in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring inhibition of 17?-hydroxysteroid dehydrogenase enzymes.Type: GrantFiled: June 7, 2004Date of Patent: December 16, 2008Assignee: Solvay Pharmaceuticals B.V.Inventors: Leena Hirvelae, Nina Johansson, Pasi Koskimies, Olli Pentikaeinen, Tommi Nyroenen, Tiina Salminen, Mark Johnson, Pekka Lehtovuori
-
Publication number: 20080306053Abstract: The present invention provides screening methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap domains of the chemosensory receptors as well as modifiers capable of modulating chemosensory receptors and their ligands.Type: ApplicationFiled: August 8, 2007Publication date: December 11, 2008Applicant: SENOMYX, INC.Inventors: Catherine Tachdjian, Xiao-Qing Tang, Sara Werner, Marketa Rinnova, Qing Chen, Guy Servant, Xiaodong Li, Feng Zhang, Haitian Liu, Albert Zlotnik, Mark Zoller, Boris Klebansky, Richard Fine, Xinshan Kang
-
Publication number: 20080300264Abstract: The present invention is directed to substituted thiatriazaacenaphthylene-6-carbonitrile compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.Type: ApplicationFiled: August 14, 2008Publication date: December 4, 2008Inventors: Peter J. Connolly, Stuart L. Emanuel, Stuart Hayden, Sigmond G. Johnson, Bharat Lagu, Steven A. Middleton, Niranjan B. Pandey, Mark T. Powell
-
Patent number: 7459459Abstract: Tri-heterocyclic compound of formula (I) wherein each of W, X and Y is carbon or nitrogen; each of U and Z is CR2, NR13, nitrogen, oxygen, sulfur etc.; A ring is carbocyclic ring, heterocyclic ring; R1 is alkyl, alkenyl, alkynyl, NR4R5, OR6 etc.; R3 is carbocyclic ring, heterocyclic ring; and a pharmaceutically acceptable salt thereof, a process for the preparation thereof, a pharmaceutical comprising them as an active ingredient. A compound of formula (I) is useful, in order to possess corticotropin releasing factor receptor antagonistic activity, for the prevention and/or treatment of depression, anxiety, eating disorder, posttraumatic stress disorder, peptic ulcer, irritable bowl syndrome, Alzheimer's disease, drug addiction or alcohol dependence syndrome etc.Type: GrantFiled: September 7, 2005Date of Patent: December 2, 2008Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Hisao Nakai, Yoshifumi Kagamiishi
-
Publication number: 20080292626Abstract: This invention relates to the compounds of formula (I) shown below. Each variable in formula (I) is defined in the specification. These compounds can be used to treat a kinesin Eg5 protein-mediated disorder.Type: ApplicationFiled: May 22, 2008Publication date: November 27, 2008Applicant: TaiGen Biotechnology Co., Ltd.Inventors: Ching-Cheng Wang, Hung-Chuan Chen, Shu-Huei Wang, Mei-Chun Lin, Tien-Lan Shieh, Ying-Huey Huang, Shih-Chieh Chuang, Chi-Hsin Richard King
-
Publication number: 20080267911Abstract: Compounds of formula (I), combinations and uses thereof for disease therapy, or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof wherein: R1 represents and R2, R3, R4, R5, R6, X1, X2, X3, X4, Y and Z are as defined throughout the description and the claims.Type: ApplicationFiled: April 18, 2008Publication date: October 30, 2008Applicant: PROBIODRUG AGInventors: Mirko Buchholz, Ulrich Heiser
-
Publication number: 20080269239Abstract: The present invention relates to novel pyrimidine compounds, for the modulation of the histamine H4 receptor and the treatment or prevention of conditions mediated by the histamine H4 receptor. The invention also relates to the preparation of such compounds.Type: ApplicationFiled: November 11, 2005Publication date: October 30, 2008Applicant: Argenta Discovery Ltd.Inventors: Neil Harris, Christopher Higgs, Stephen Wren, Hazel Dyke, Steven Price, Sue Cramp
-
Publication number: 20080269486Abstract: Various embodiment of the present invention are directed to organic molecules that are reconfigurable under application of an external electric field. One organic molecule embodiment of the present invention has the structure: where L1X1 and L2X2 are optional connector groups, A represents an electron acceptor group, D represents an electron donor group, R and R? represent spacer molecules, and R1, R2, R3, R4, R5, R6, R7, and R8 represent atoms and hydrocarbons.Type: ApplicationFiled: April 30, 2007Publication date: October 30, 2008Inventors: Zhang-Lin Zhou, Zhiyong Li
-
Patent number: 7442710Abstract: The present invention relates to compounds of general formula IA or IB wherein X1 and X2 are each independently N or C—R? and R1, R2,R3, R4, R5, and R6 are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The compounds can be used for the treatment of diseases related to the glycine transporter inhibitor, such as schizophrenia and Alzheimer's disease.Type: GrantFiled: January 24, 2006Date of Patent: October 28, 2008Assignee: Hoffman-La Roche Inc.Inventors: Synese Jolidon, Robert Narquizian, Roger David Norcross, Emmanuel Pinard
-
Publication number: 20080261946Abstract: The present invention relates to novel pyrimidine compounds, for the modulation of the histamine H4 receptor and the treatment or prevention of conditions mediated by the histamine H4 receptor. The invention also relates to the preparation of such compounds.Type: ApplicationFiled: September 20, 2006Publication date: October 23, 2008Applicant: CELLZOME (UK) LTD.Inventors: Hazel Dyke, Steven Price, Sue Cramp
-
Patent number: 7439249Abstract: The present invention relates to compounds that inhibit phosphatases, compositions thereof, and methods of using those compounds and compositions for treating diseases.Type: GrantFiled: December 31, 2003Date of Patent: October 21, 2008Assignee: Vertex Pharmaceuticals IncorporatedInventors: Jeffrey O. Saunders, Gregory F. Miknis, Alexandre J. Buckmelter, Kevin W. Hunt, James F. Blake, Guy P. A. Vigers, Xicheng Sun
-
Publication number: 20080234300Abstract: The present invention relates to pyrimido[5,4-c]quinoline-2,4-diamine derivatives, compositions comprising an effective amount of a Pyrimido[5,4-c]quinoline-2,4-diamine Derivative, methods for treating or preventing a proliferative disorder, comprising administering to a subject in need thereof an effective amount of an Pyrimido[5,4-c]quinoline-2,4-diamine Derivative, methods for modulating PDK-1 activity, comprising administering to a subject in need thereof an effective amount of a Pyrimido[5,4-c]quinoline-2,4-diamine Derivative. The invention also relates to a process for preparing a Pyrimido[5,4-c]quinoline-2,4-diamine Derivative.Type: ApplicationFiled: March 4, 2008Publication date: September 25, 2008Applicant: WYETHInventors: Allan WISSNER, Aranapakam M. VENKATESAN
-
Patent number: 7427625Abstract: The present invention is directed to substituted thiatriazaacenaphthylene-6-carbonitrile compounds of formula (I): and forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.Type: GrantFiled: February 7, 2007Date of Patent: September 23, 2008Assignee: Janssen Pharmaceutica, N.V.Inventors: Peter J. Connolly, Stuart L. Emanuel, Stuart Hayden, Sigmond G. Johnson, Bharat Lagu, Steven A. Middleton, Niranjan B. Pandey, Mark T. Powell
-
Publication number: 20080227979Abstract: The present invention relates to pyrido[3,2-h]quinazolines and/or 5,6-dihydro derivatives thereof, methods for their production and doped organic semiconductor material which use such quinazolines.Type: ApplicationFiled: March 12, 2008Publication date: September 18, 2008Applicant: NOVALED AGInventors: Josef Saalbeck, Manfred Kussler, Andrea Lux
-
Publication number: 20080227684Abstract: The present invention relates to compositions for use in the modulation of PDZ domain interactions with cognate ligands. Methods of assessing and characterizing PDZ domain interactions from various polypeptides also are provided.Type: ApplicationFiled: December 29, 2006Publication date: September 18, 2008Inventors: MICHAEL P. BELMARES, Peter S. Lu, Kenneth A. Mendoza
-
PHARMACEUTICAL FORMULATIONS COMPRISING SALTS OF A PROTEIN KINASE INHIBITOR AND METHODS OF USING SAME
Publication number: 20080226747Abstract: The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer.Type: ApplicationFiled: March 3, 2008Publication date: September 18, 2008Applicant: SUPERGEN, INC.Inventors: David J. Bearss, Rajashree Joshi-Hangal, Xiao-Hui Liu, Pasit Phiasivongsa, Sanjeev G. Redkar, Hariprasad Vankayalapati -
Publication number: 20080207632Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer, such as Aurora kinase-expressing cancers and Axl kinase-expressing cancers. Compounds of the invention have the following structure: including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Z, L2 and w are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.Type: ApplicationFiled: October 31, 2007Publication date: August 28, 2008Applicant: SUPERGEN, INC.Inventors: David J. Bearss, Cory L. Grand, Xiao-Hui Liu, Hariprasad Vankayalapati
-
Publication number: 20080207607Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.Type: ApplicationFiled: November 20, 2007Publication date: August 28, 2008Inventors: Christian Gege, Carine Chevrier, Matthias Schneider, Harald Bluhm, Matthias Hochgurtel, Hongbo Deng, Brian M. Gallagher, Irving Sucholeiki, Arthur Taveras